Loading viewer...
investor_presentation
Format: PDF investor_presentation
Accelerate Diagnostics presented its Accelerate Pheno® rapid AST platform, the first FDA-approved rapid antimicrobial susceptibility testing system with strong clinical impact. The company outlined commercialization plans for Wave™ and Arc™ platforms targeting a $2B AST market, with expected clinical trials in Q2 2024 and FDA submission in Q3 2024, alongside a commercial partnership with Becton Dickinson.
First Republic Bank Investor Presentation — October 2022
investor_presentationinvestor_presentation
56 Pages
First Republic Bank
investor_presentation
Silex Systems
investor_presentation
18 Pages